PeptideScanner corrections, routine public-version updates, and source-published research-integrity notices remain separate. Earlier public versions remain available rather than being silently erased.
Material record
Corrections and retractions
Factual errors, withdrawals, and retractions appear here separately from routine wording or source updates.
We refreshed this profile's label citation to the reviewed SPL version 19, published 2026-08-17. Earlier profile versions retain their original label citations. The product-specific label account identifies its reviewed scope.
We clarified that CJC-1295 with DAC is a related, distinct active moiety rather than an interchangeable form. The FDA briefing describes five bulk substances; clinical findings must retain the studied form.
PeptideScanner change date
September 15, 2026
Evidence lane
Profile
Profile summary
Before
A peptide named in FDA compounding-risk and DOJ enforcement records.
After
FDA evaluates CJC-1295 and CJC-1295 with drug affinity complex (DAC) as distinct active moieties, with several salt forms.
Evidence note
Before
FDA's compounding-risk page describes immunogenicity, impurity, and adverse-event concerns. A separate Justice Department release names CJC 1295 among unapproved new drugs distributed by the cited pharmacy.
After
FDA's 2024 briefing distinguishes five bulk substances and reports that none is a component of an FDA-approved drug. Evidence for a DAC-modified substance cannot automatically establish effects for a non-DAC form.
We refreshed this profile's label citation to the reviewed SPL version 62, published 2026-08-10. Earlier profile versions retain their original label citations. The product-specific label account identifies its reviewed scope.
The previous profile described elamipretide only as investigational. We added FDA's September 19, 2025 accelerated approval of Forzinity for the specified Barth syndrome population. This correction does not extend that approval to other uses or formulations.
PeptideScanner change date
September 15, 2026
Evidence lane
Profile
Status
Before
Investigational
After
U.S. accelerated approval for a specified Barth syndrome population
Status classification
Before
investigational
After
approved
Profile summary
Before
A mitochondria-targeting peptide candidate. This profile cites a recruiting ClinicalTrials.gov study record.
After
FDA granted Forzinity (elamipretide) accelerated approval to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg.
Evidence note
Before
ClinicalTrials.gov lists the 4TAZPower study as recruiting, updated July 13, 2026.
After
FDA's September 19, 2025 approval letter requires a confirmatory trial to verify clinical benefit. The approval concerns this product and specified use; a recruiting trial record does not describe its full regulatory status.
We narrowed the status wording to what the dated FDA briefing establishes. A briefing prepared for an advisory process does not establish the current absence of a later final decision. Related substance identities remain distinct.
PeptideScanner change date
September 15, 2026
Evidence lane
Profile
Status
Before
FDA compounding safety review; final determination pending
After
FDA compounding assessment in the cited records
Evidence note
Before
FDA's emideltide briefing describes evidence and safety questions presented to the advisory committee. Committee recommendations are nonbinding, and FDA says its final determination will follow completion of the committee process and relevant reviews.
After
FDA's July 2026 briefing evaluates Emideltide-related bulk drug substances for pharmacy compounding. The briefing is an advisory-process assessment, not a final regulatory determination.
We narrowed the status wording to what the dated FDA briefing establishes. A briefing prepared for an advisory process does not establish the current absence of a later final decision. Related substance identities remain distinct.
PeptideScanner change date
September 15, 2026
Evidence lane
Profile
Status
Before
FDA compounding safety review; final determination pending
After
FDA compounding assessment in the cited records
Evidence note
Before
FDA's Epitalon briefing describes evidence and safety questions presented to the advisory committee. Committee recommendations are nonbinding, and FDA says its final determination will follow completion of the committee process and relevant reviews.
After
FDA's July 2026 briefing evaluates epitalon free base and acetate and distinguishes the tetrapeptide from epithalamin, a pineal-gland extract. The briefing is an advisory-process assessment, not a final regulatory determination.
The previous summary described this only as an emergency-treatment label. We now distinguish Gvoke's severe-hypoglycemia indication from Gvoke VialDx's diagnostic indication in the same cited label.
PeptideScanner change date
September 15, 2026
Evidence lane
Profile
Profile summary
Before
A peptide hormone. This profile cites a U.S. emergency-treatment label.
After
A peptide hormone. The cited U.S. label distinguishes Gvoke for severe hypoglycemia from Gvoke VialDx for diagnostic use.
Evidence note
Before
The cited DailyMed label identifies Glucagon and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
After
The cited label describes subcutaneous Gvoke for severe hypoglycemia in people with diabetes aged two years and older, and intravenous Gvoke VialDx as a diagnostic aid in adults. The product, route and indication must remain distinct.
We added FDA's dated assessment to distinguish substance forms, evaluated uses and the advisory stage of review. Earlier profile versions remain available.
PeptideScanner change date
September 15, 2026
Evidence lane
Profile
Profile summary
Before
A peptide named in FDA compounding-risk and DOJ enforcement records.
After
FDA's August 2024 assessment distinguishes ipamorelin free base and acetate and evaluates evidence for growth hormone deficiency and postoperative ileus.
Evidence note
Before
FDA's compounding-risk page describes immunogenicity and characterization concerns. A separate Justice Department release names Ipamorelin among unapproved new drugs distributed by the cited pharmacy.
After
At the time of its assessment, FDA reported that neither form was a component of an FDA-approved drug and found insufficient evidence for the evaluated uses. The advisory briefing is not a final compounding determination.
We narrowed the status wording to what the dated FDA briefing establishes. A briefing prepared for an advisory process does not establish the current absence of a later final decision. Related substance identities remain distinct.
PeptideScanner change date
September 15, 2026
Evidence lane
Profile
Status
Before
FDA compounding safety review; final determination pending
After
FDA compounding assessment in the cited records
Evidence note
Before
FDA's KPV briefing describes evidence and safety questions presented to the advisory committee. Committee recommendations are nonbinding, and FDA says its final determination will follow completion of the committee process and relevant reviews.
After
FDA's July 2026 briefing evaluates KPV-related bulk drug substances for pharmacy compounding. The briefing is an advisory-process assessment, not a final regulatory determination.
The previous profile used an unqualified investigational status. We added dated local-government reports of approval in China while keeping national decision and label verification open. Earlier trial-based versions remain available.
PeptideScanner change date
September 15, 2026
Evidence lane
Profile
Status
Before
Investigational
After
China: approval reported by local government sources
Status classification
Before
investigational
After
approval-reported
Profile summary
Before
A metabolic peptide candidate. This profile cites a ClinicalTrials.gov study record that was not yet recruiting.
After
A June 2025 Suzhou Industrial Park regulator report describes Chinese approval of mazdutide injection for long-term weight management in adults with obesity or overweight. A December 2025 Suzhou government report describes approved diabetes and weight-management indications in China.
Evidence note
Before
ClinicalTrials.gov lists a West China Hospital study as not yet recruiting, updated July 21, 2026.
After
These are attributable local-government reports, not the national approval decision or complete prescribing information. The national decision and exact indication conditions remain to be reconciled. This account does not establish approval in the United States or other jurisdictions.
We narrowed the status wording to what the dated FDA briefing establishes. A briefing prepared for an advisory process does not establish the current absence of a later final decision. Related substance identities remain distinct.
PeptideScanner change date
September 15, 2026
Evidence lane
Profile
Status
Before
FDA compounding safety review
After
FDA compounding assessment in the cited records
Evidence note
Before
FDA presented MOTS-c briefing material at its July 2026 pharmacy-compounding advisory-committee meeting. Committee recommendations are nonbinding, and FDA says its final determination will follow completion of the committee process and relevant reviews.
After
FDA's July 2026 briefing evaluates MOTS-c-related bulk drug substances for pharmacy compounding. The briefing is an advisory-process assessment, not a final regulatory determination.
We narrowed the status wording to what the dated FDA briefing establishes. A briefing prepared for an advisory process does not establish the current absence of a later final decision. Related substance identities remain distinct.
PeptideScanner change date
September 15, 2026
Evidence lane
Profile
Status
Before
FDA compounding safety review; final determination pending
After
FDA compounding assessment in the cited records
Evidence note
Before
FDA's Semax briefing describes evidence and safety questions presented to the advisory committee. Committee recommendations are nonbinding, and FDA says its final determination will follow completion of the committee process and relevant reviews.
After
FDA's July 2026 briefing evaluates Semax-related bulk drug substances for pharmacy compounding. The briefing is an advisory-process assessment, not a final regulatory determination.
We narrowed the status wording to what the dated FDA briefing establishes. A briefing prepared for an advisory process does not establish the current absence of a later final decision. Related substance identities remain distinct.
PeptideScanner change date
September 15, 2026
Evidence lane
Profile
Status
Before
FDA compounding safety review; final determination pending
After
FDA compounding assessment in the cited records
Evidence note
Before
FDA's identity record maps TB-500 to a thymosin beta-4 fragment, while FDA's July 2026 briefing addresses its pharmacy-compounding review. Committee recommendations are nonbinding, and FDA's final determination remains pending.
After
FDA's July 2026 briefing evaluates TB-500-related bulk drug substances for pharmacy compounding. The briefing is an advisory-process assessment, not a final regulatory determination.
We refreshed this profile's label citation to the reviewed SPL version 9, published 2026-07-31. Earlier profile versions retain their original label citations. The product-specific label account identifies its reviewed scope.
We refreshed this profile's label citation to the reviewed SPL version 40, published 2026-09-02. Earlier profile versions retain their original label citations. The product-specific label account identifies its reviewed scope.
These entries preserve wording changes or ordinary source-record updates. An entry here does not by itself mean the earlier version contained a factual error.
We added FDA’s May 2026 503A nominations list, which places GHRP-2 in category 3, and two human studies of its effect on growth hormone and appetite and its use as a diagnostic test.
PeptideScanner change date
November 16, 2026
Evidence lane
Profile
Evidence note
Before
FDA reports serious adverse events in patients who received GHRP-2, with causality not established. No FDA approval is reported in the cited sources, and GHRP-2 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.
After
Small human studies report that GHRP-2 raises growth hormone and appetite, and test it as a diagnostic. FDA reports serious adverse events in patients who received GHRP-2, with causality not established. No FDA approval is reported, and GHRP-2 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.
We now state that the label calls Langlara biosimilar to Lantus, and that the trials in its label are the reference product’s trials, which the Lantus label describes as trials of Lantus. We also no longer suggest that an unread page of the approval letter might hold FDA’s findings: it does not.
PeptideScanner change date
November 16, 2026
Evidence lane
Profile
Evidence note
Before
FDA’s approval letter describes the application as seeking licensure as biosimilar to and interchangeable with US-licensed Lantus. The clinical studies in the label are insulin glargine studies against NPH insulin, not trials of insulin glargine-aldy itself.
After
Its label states that it is biosimilar to Lantus. The trials in the label are the insulin glargine trials against NPH insulin, which the Lantus label describes as trials of Lantus; no trial of insulin glargine-aldy itself is described in the sources reviewed here.
We added three randomized trials of LL-37 in chronic ulcers, FDA’s advisory committee page listing LL-37 for a meeting before the end of February 2027, and the spelling LL37 that trial registrations use, so that those registrations are matched.
PeptideScanner change date
November 16, 2026
Evidence lane
Profile
Profile summary
Before
A 37-amino-acid human cathelicidin peptide, also called ropocamptide, that FDA lists among compounding substances that may present significant safety risks.
After
A 37-amino-acid human cathelicidin peptide, also called ropocamptide, tested in small trials in chronic ulcers. FDA lists it among compounding substances that may present significant safety risks.
Evidence note
Before
FDA states that it lacks sufficient safety information on LL-37 in people and cites nonclinical findings of harm to male reproduction and tumor promotion. LL-37 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.
After
Three small randomized trials in chronic leg and foot ulcers report mixed results; the largest found no significant difference from placebo. FDA states that it lacks sufficient safety information on LL-37 in people. LL-37 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.
We added two early human studies of Melanotan II and FDA’s advisory committee page listing it for a meeting before the end of February 2027.
PeptideScanner change date
November 16, 2026
Evidence lane
Profile
Evidence note
Before
FDA cites published case reports of melanoma, brain swelling, stimulant-like toxicity and priapism in people who used Melanotan II. No FDA approval is reported in the cited sources, and it is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.
After
Two very small early human studies, one placebo-controlled in 10 men, report skin darkening, erections and nausea. FDA cites case reports of melanoma, brain swelling, stimulant-like toxicity and priapism. No FDA approval is reported, and it is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.
We added the FDA labels of Sandostatin LAR and Mycapssa and now describe each trial with the octreotide product it tested, because the generic label cited on this page has no clinical studies section.
PeptideScanner change date
November 16, 2026
Evidence lane
Profile
Evidence note
Before
The cited label states that its trials did not show improvement in symptoms or tumor size. Smaller randomized trials in acromegaly report lower growth hormone and IGF-1 levels.
After
The generic label cited here describes no trials of its own and states that its trials did not show improvement in symptoms or tumor size. Randomized trials of two other octreotide products, Sandostatin LAR and Mycapssa, are described in their own FDA labels.
We added the published results of the ZUPREME 1 Phase 2 trial and two more ClinicalTrials.gov records. Earlier versions said the only published human results were from Phase 1 trials.
PeptideScanner change date
November 16, 2026
Evidence lane
Profile
Evidence note
Before
The only published human results reviewed here are from two small randomized Phase 1 trials, which reported weight reductions. Phase 2 trials are listed as completed without results in the sources cited, and Phase 3 trials were recruiting in late 2026.
After
A published randomized, placebo-controlled Phase 2 trial in 485 adults with obesity (ZUPREME 1) reported average weight reductions of about 8% to 10% at 28 weeks, against about 2% with placebo; nausea was the most common side effect. Phase 3 trials were recruiting in late 2026.
We added a 2015 Russian clinical study of selank added to phenazepam in patients with anxiety disorders. Earlier versions said no human study was cited among the sources reviewed.
PeptideScanner change date
November 16, 2026
Evidence lane
Profile
Evidence note
Before
No human study is cited in the reviewed sources; the published work cited here is in rats. No FDA approval is reported, and selank is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.
After
The only human study found is a small 2015 Russian study of selank added to phenazepam in anxiety disorders, checkable only from its abstract; the other published work cited here is in rats. No FDA approval is reported, and selank is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.
ClinicalTrials.gov posted a newer version of NCT04775082, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 16, 2026
Cited source date
November 16, 2026
Evidence lane
Clinical trials
Summary
Before
PeptideScanner retained ClinicalTrials.gov record NCT04775082 at 2026-08-10T18:10:04.224Z. Its registry update date was 2026-07-09, and PeptideScanner's reviewed identity mapping was liraglutide.
After
PeptideScanner retained ClinicalTrials.gov record NCT04775082 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was liraglutide.
1. PeptideScanner retained ClinicalTrials.gov record NCT04775082 at 2026-08-10T18:10:04.224Z. Its registry update date was 2026-07-09, and PeptideScanner's reviewed identity mapping was liraglutide. [sources: ctg-observation-nct04775082-2026-07-09-b565460c570f]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct04775082-2026-07-09-b565460c570f]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT04775082 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was liraglutide. [sources: ctg-observation-nct04775082-2026-07-09-b565460c570f-r2]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct04775082-2026-07-09-b565460c570f-r2]
ClinicalTrials.gov posted a newer version of NCT05278208, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 16, 2026
Cited source date
November 16, 2026
Evidence lane
Clinical trials
Summary
Before
PeptideScanner retained ClinicalTrials.gov record NCT05278208 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-07-20, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.
After
PeptideScanner retained ClinicalTrials.gov record NCT05278208 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.
1. PeptideScanner retained ClinicalTrials.gov record NCT05278208 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-07-20, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. [sources: ctg-observation-nct05278208-2026-07-20-294c4af79959]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct05278208-2026-07-20-294c4af79959]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT05278208 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. [sources: ctg-observation-nct05278208-2026-07-20-294c4af79959-r2]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct05278208-2026-07-20-294c4af79959-r2]
ClinicalTrials.gov posted a newer version of NCT05669664, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 16, 2026
Cited source date
November 16, 2026
Evidence lane
Clinical trials
Summary
Before
PeptideScanner retained ClinicalTrials.gov record NCT05669664 at 2026-07-30T16:19:03.066Z. Its registry update date was 2026-06-17, and PeptideScanner's reviewed identity mapping was leuprolide.
After
PeptideScanner retained ClinicalTrials.gov record NCT05669664 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was leuprolide.
1. PeptideScanner retained ClinicalTrials.gov record NCT05669664 at 2026-07-30T16:19:03.066Z. Its registry update date was 2026-06-17, and PeptideScanner's reviewed identity mapping was leuprolide. [sources: ctg-observation-nct05669664-2026-06-17-1cc9e92daca2]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct05669664-2026-06-17-1cc9e92daca2]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT05669664 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was leuprolide. [sources: ctg-observation-nct05669664-2026-06-17-1cc9e92daca2-r2]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct05669664-2026-06-17-1cc9e92daca2-r2]
ClinicalTrials.gov posted a newer version of NCT06015893, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 16, 2026
Cited source date
November 16, 2026
Evidence lane
Clinical trials
Summary
Before
PeptideScanner retained ClinicalTrials.gov record NCT06015893 at 2026-08-13T05:52:27.015Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was semaglutide.
After
PeptideScanner retained ClinicalTrials.gov record NCT06015893 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was semaglutide.
1. PeptideScanner retained ClinicalTrials.gov record NCT06015893 at 2026-08-13T05:52:27.015Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was semaglutide. [sources: ctg-observation-nct06015893-2026-08-03-32ebc1c71794]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06015893-2026-08-03-32ebc1c71794]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT06015893 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was semaglutide. [sources: ctg-observation-nct06015893-2026-08-03-32ebc1c71794-r2]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06015893-2026-08-03-32ebc1c71794-r2]
ClinicalTrials.gov posted a newer version of NCT07220759, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 16, 2026
Cited source date
November 16, 2026
Evidence lane
Clinical trials
Summary
Before
PeptideScanner retained ClinicalTrials.gov record NCT07220759 at 2026-08-13T05:52:27.019Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was cagrilintide.
After
PeptideScanner retained ClinicalTrials.gov record NCT07220759 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was cagrilintide.
1. PeptideScanner retained ClinicalTrials.gov record NCT07220759 at 2026-08-13T05:52:27.019Z. Its registry update date was 2026-08-03, and PeptideScanner's reviewed identity mapping was cagrilintide. [sources: ctg-observation-nct07220759-2026-08-03-50fb10a6adbd]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07220759-2026-08-03-50fb10a6adbd]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT07220759 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was cagrilintide. [sources: ctg-observation-nct07220759-2026-08-03-50fb10a6adbd-r2]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07220759-2026-08-03-50fb10a6adbd-r2]
ClinicalTrials.gov posted a newer version of NCT07843472, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 16, 2026
Cited source date
November 16, 2026
Evidence lane
Clinical trials
Summary
Before
PeptideScanner retained ClinicalTrials.gov record NCT07843472 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-07, and PeptideScanner's reviewed identity mapping was petrelintide.
After
PeptideScanner retained ClinicalTrials.gov record NCT07843472 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was petrelintide.
1. PeptideScanner retained ClinicalTrials.gov record NCT07843472 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-07, and PeptideScanner's reviewed identity mapping was petrelintide. [sources: ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT07843472 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was petrelintide. [sources: ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b-r2]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07843472-2026-10-07-b4d7f3eecf4b-r2]
PubMed revised the bibliographic metadata of PMID 40484968, with a metadata revision date of 2026-10-14. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 16, 2026
Cited source date
October 14, 2026
Evidence lane
Literature metadata
Summary
Before
PubMed lists PMID 40484968 in Orphanet journal of rare diseases as Journal Article, with publication-date metadata of 2025-06-08 (day precision). PeptideScanner associated the retained record with the identity slug setmelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
After
PubMed lists PMID 40484968 in Orphanet journal of rare diseases as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-06-08 (day precision). PeptideScanner associated the retained record with the identity slug setmelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
1. PubMed lists PMID 40484968 in Orphanet journal of rare diseases as Journal Article, with publication-date metadata of 2025-06-08 (day precision). PeptideScanner associated the retained record with the identity slug setmelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-40484968-2025-06-11-ad972f169e99]
2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-40484968-2025-06-11-ad972f169e99]
After
1. PubMed lists PMID 40484968 in Orphanet journal of rare diseases as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2025-06-08 (day precision). PeptideScanner associated the retained record with the identity slug setmelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-40484968-2025-06-11-ad972f169e99-r2]
2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-40484968-2025-06-11-ad972f169e99-r2]
PubMed revised the bibliographic metadata of PMID 42196730, with a metadata revision date of 2026-11-01. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 16, 2026
Cited source date
November 1, 2026
Evidence lane
Literature metadata
Summary
Before
PubMed lists PMID 42196730 in International journal of environmental research and public health as Journal Article, with publication-date metadata of 2026-05-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
After
PubMed lists PMID 42196730 in International journal of environmental research and public health as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-05-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
1. PubMed lists PMID 42196730 in International journal of environmental research and public health as Journal Article, with publication-date metadata of 2026-05-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c]
2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c]
After
1. PubMed lists PMID 42196730 in International journal of environmental research and public health as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-05-12 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c-r2]
2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42196730-2026-07-17-4b8a02c2889c-r2]
PubMed revised the bibliographic metadata of PMID 42270043, with a metadata revision date of 2026-10-28. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 16, 2026
Cited source date
October 28, 2026
Evidence lane
Literature metadata
Summary
Before
PubMed lists PMID 42270043 in Molecular metabolism as Journal Article, with publication-date metadata of 2026-06-10 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
After
PubMed lists PMID 42270043 in Molecular metabolism as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-06-10 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
1. PubMed lists PMID 42270043 in Molecular metabolism as Journal Article, with publication-date metadata of 2026-06-10 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42270043-2026-07-26-50837ea3dd38]
2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42270043-2026-07-26-50837ea3dd38]
After
1. PubMed lists PMID 42270043 in Molecular metabolism as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-06-10 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42270043-2026-07-26-50837ea3dd38-r2]
2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42270043-2026-07-26-50837ea3dd38-r2]
PubMed revised the bibliographic metadata of PMID 42400596, with a metadata revision date of 2026-11-04. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 16, 2026
Cited source date
November 4, 2026
Evidence lane
Literature metadata
Summary
Before
PubMed lists PMID 42400596 in Clinical chemistry as Journal Article, with publication-date metadata of 2026-07-04 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
After
PubMed lists PMID 42400596 in Clinical chemistry as Journal Article, Comparative Study, with publication-date metadata of 2026-11-04 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
1. PubMed lists PMID 42400596 in Clinical chemistry as Journal Article, with publication-date metadata of 2026-07-04 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42400596-2026-07-04-ae5da0e1b583]
2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42400596-2026-07-04-ae5da0e1b583]
After
1. PubMed lists PMID 42400596 in Clinical chemistry as Journal Article, Comparative Study, with publication-date metadata of 2026-11-04 (day precision). PeptideScanner associated the retained record with the identity slug glucagon. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42400596-2026-07-04-ae5da0e1b583-r2]
2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42400596-2026-07-04-ae5da0e1b583-r2]
PubMed revised the bibliographic metadata of PMID 42432542, with a metadata revision date of 2026-10-09. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 16, 2026
Cited source date
October 9, 2026
Evidence lane
Literature metadata
Summary
Before
PubMed lists PMID 42432542 in BMC ophthalmology as Journal Article, with publication-date metadata of 2026-07-10 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
After
PubMed lists PMID 42432542 in BMC ophthalmology as Journal Article, Case Reports, with publication-date metadata of 2026-07-10 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
1. PubMed lists PMID 42432542 in BMC ophthalmology as Journal Article, with publication-date metadata of 2026-07-10 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313]
2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313]
After
1. PubMed lists PMID 42432542 in BMC ophthalmology as Journal Article, Case Reports, with publication-date metadata of 2026-07-10 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313-r2]
2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42432542-2026-07-10-5adc8b896313-r2]
PubMed revised the bibliographic metadata of PMID 42469146, with a metadata revision date of 2026-11-03. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 16, 2026
Cited source date
November 3, 2026
Evidence lane
Literature metadata
Summary
Before
PubMed lists PMID 42469146 in Nutrition, metabolism, and cardiovascular diseases : NMCD as Journal Article, with publication-date metadata of 2026-07-16 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
After
PubMed lists PMID 42469146 in Nutrition, metabolism, and cardiovascular diseases : NMCD as Journal Article, Review, Consensus Statement, with publication-date metadata of 2026-07-16 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
1. PubMed lists PMID 42469146 in Nutrition, metabolism, and cardiovascular diseases : NMCD as Journal Article, with publication-date metadata of 2026-07-16 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55]
2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55]
After
1. PubMed lists PMID 42469146 in Nutrition, metabolism, and cardiovascular diseases : NMCD as Journal Article, Review, Consensus Statement, with publication-date metadata of 2026-07-16 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55-r2]
2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42469146-2026-07-17-b145ec90ac55-r2]
PubMed revised the bibliographic metadata of PMID 42478204, with a metadata revision date of 2026-09-28. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 16, 2026
Cited source date
September 28, 2026
Evidence lane
Literature metadata
Headline
Before
Octreotide in the Management of Chyle Leaks After Head and Neck Surgery: A Systematic Review of Cohort Studies.
After
Octreotide in the management of chyle leaks after head and neck surgery: a systematic review of cohort studies.
1. PubMed lists PMID 42478204 in The Journal of laryngology and otology as Journal Article, Review, with publication-date metadata of 2026-07-21 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42478204-2026-07-21-1c4af7971ca8]
2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42478204-2026-07-21-1c4af7971ca8]
After
1. PubMed lists PMID 42478204 in The Journal of laryngology and otology as Journal Article, Review, with publication-date metadata of 2026-07-21 (day precision). PeptideScanner associated the retained record with the identity slug octreotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42478204-2026-07-21-1c4af7971ca8-r2]
2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42478204-2026-07-21-1c4af7971ca8-r2]
PubMed revised the bibliographic metadata of PMID 42708757, with a metadata revision date of 2026-09-11. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 16, 2026
Cited source date
September 11, 2026
Evidence lane
Literature metadata
Summary
Before
PubMed lists PMID 42708757 in Analytical chemistry as Journal Article, with publication-date metadata of 2026-09-08 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
After
PubMed lists PMID 42708757 in Analytical chemistry as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-09-08 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
1. PubMed lists PMID 42708757 in Analytical chemistry as Journal Article, with publication-date metadata of 2026-09-08 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42708757-2026-09-08-e64e298b159c]
2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42708757-2026-09-08-e64e298b159c]
After
1. PubMed lists PMID 42708757 in Analytical chemistry as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-09-08 (day precision). PeptideScanner associated the retained record with the identity slug liraglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42708757-2026-09-08-e64e298b159c-r2]
2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42708757-2026-09-08-e64e298b159c-r2]
PubMed revised the bibliographic metadata of PMID 42709517, with a metadata revision date of 2026-10-30. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 16, 2026
Cited source date
October 30, 2026
Evidence lane
Literature metadata
Headline
Before
Development of Chondroitin Sulfate ‑ Stabilized PLGA Microspheres of Exenatide via Polarity Gradient Extraction.
After
Development of chondroitin sulfate‑stabilized PLGA microspheres of exenatide via polarity gradient extraction.
Summary
Before
PubMed lists PMID 42709517 in Pharmaceutical development and technology as Journal Article, with publication-date metadata of 2026-09-08 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
After
PubMed lists PMID 42709517 in Pharmaceutical development and technology as Journal Article, with publication-date metadata of 2026-09-18 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
1. PubMed lists PMID 42709517 in Pharmaceutical development and technology as Journal Article, with publication-date metadata of 2026-09-08 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42709517-2026-09-08-8c8d68644f0e]
2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42709517-2026-09-08-8c8d68644f0e]
After
1. PubMed lists PMID 42709517 in Pharmaceutical development and technology as Journal Article, with publication-date metadata of 2026-09-18 (day precision). PeptideScanner associated the retained record with the identity slug exenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42709517-2026-09-08-8c8d68644f0e-r2]
2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42709517-2026-09-08-8c8d68644f0e-r2]
PubMed revised the bibliographic metadata of PMID 42713641, with a metadata revision date of 2026-11-09. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 16, 2026
Cited source date
November 9, 2026
Evidence lane
Literature metadata
Summary
Before
PubMed lists PMID 42713641 in NEJM evidence as Journal Article, with publication-date metadata of 2026-09-09 (day precision). PeptideScanner associated the retained record with the identity slug vosoritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
After
PubMed lists PMID 42713641 in NEJM evidence as Journal Article, Clinical Trial, Phase III, Randomized Controlled Trial, Multicenter Study, with publication-date metadata of 2026-09-09 (day precision). PeptideScanner associated the retained record with the identity slug vosoritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
1. PubMed lists PMID 42713641 in NEJM evidence as Journal Article, with publication-date metadata of 2026-09-09 (day precision). PeptideScanner associated the retained record with the identity slug vosoritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42713641-2026-09-09-3296b303c913]
2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42713641-2026-09-09-3296b303c913]
After
1. PubMed lists PMID 42713641 in NEJM evidence as Journal Article, Clinical Trial, Phase III, Randomized Controlled Trial, Multicenter Study, with publication-date metadata of 2026-09-09 (day precision). PeptideScanner associated the retained record with the identity slug vosoritide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. [sources: pubmed-observation-pmid-42713641-2026-09-09-3296b303c913-r2]
2. This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. [sources: pubmed-observation-pmid-42713641-2026-09-09-3296b303c913-r2]
We added the six Novo Nordisk Phase 3 trials that ClinicalTrials.gov lists under the name zenagamtide, which the previous version did not describe, from registry records PeptideScanner retained on November 15, 2026.
PeptideScanner change date
November 15, 2026
Evidence lane
Profile
Profile summary
Before
An experimental Novo Nordisk GLP-1 and amylin receptor agonist, now named zenagamtide. It is not FDA-approved.
After
An experimental Novo Nordisk GLP-1 and amylin receptor agonist, now named zenagamtide and in registered Phase 3 trials. It is not FDA-approved.
Evidence note
Before
Published randomized trials, each with fewer than 300 participants, report weight loss in early studies and lower HbA1c in a Phase 2 diabetes trial, with common gastrointestinal side effects.
After
Published randomized trials, each with fewer than 300 participants, report weight loss in early studies and lower HbA1c in a Phase 2 diabetes trial, with common gastrointestinal side effects. Phase 3 trials registered as zenagamtide have not reported results.
We added the name salmon calcitonin, which FDA’s substance registry lists for this ingredient, so that records using that name are matched. The label-based content did not change.
We re-based this profile on the current Eligard label on DailyMed (SPL version 19, published May 11, 2026), because the generic label cited before is no longer marketed or served, and now describe the studies that label reports. HERO is described only as a trial in which leuprolide was the comparison treatment. Earlier versions remain available.
PeptideScanner change date
November 15, 2026
Evidence lane
Profile
Profile summary
Before
A GnRH agonist FDA-approved since 1985 under several names. The cited label covers palliative treatment of advanced prostate cancer; FDA approved Vobrig for central precocious puberty in August 2026.
After
A GnRH agonist FDA-approved since 1985 under several names. The cited Eligard label covers advanced prostate cancer; FDA approved Vobrig for central precocious puberty in August 2026.
Evidence note
Before
The label describes a controlled comparison with another hormone treatment in prostate cancer, and leuprolide served as the comparison treatment in a large randomized trial. Each leuprolide product has its own label and uses.
After
The cited Eligard label describes four open-label studies that measured testosterone suppression in men with prostate cancer. Each leuprolide product has its own label and uses.
U.S. National Library of Medicine [sources: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10]; U.S. Food and Drug Administration [sources: fda-drugs-nda019010-1985-04-09-d97355079c93, fda-vobrig-approval-2026]
After
U.S. National Library of Medicine [sources: dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19]; U.S. Food and Drug Administration [sources: fda-drugs-nda019010-1985-04-09-d97355079c93, fda-vobrig-approval-2026]
We moved this profile to the current DailyMed label (SPL version 10, published September 21, 2026), which adds a separate warning about allergic reactions, and added the October 23, 2026 Drugs@FDA approval of a further generic teriparatide application. The previous version, citing label version 9, remains available.
U.S. National Library of Medicine [sources: dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9]; U.S. Food and Drug Administration [sources: fda-drugs-nda021318-2002-11-26-2f4c2df07e0a]
After
U.S. National Library of Medicine [sources: dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v10]; U.S. Food and Drug Administration [sources: fda-drugs-nda021318-2002-11-26-2f4c2df07e0a]
ClinicalTrials.gov posted a newer version of NCT00569127, with a registry update date of 2026-11-13. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 15, 2026
Cited source date
November 13, 2026
Evidence lane
Clinical trials
Summary
Before
PeptideScanner retained ClinicalTrials.gov record NCT00569127 at 2026-08-10T18:10:03.946Z. Its registry update date was 2026-07-29, and PeptideScanner's reviewed identity mapping was octreotide.
After
PeptideScanner retained ClinicalTrials.gov record NCT00569127 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was octreotide.
1. PeptideScanner retained ClinicalTrials.gov record NCT00569127 at 2026-08-10T18:10:03.946Z. Its registry update date was 2026-07-29, and PeptideScanner's reviewed identity mapping was octreotide. [sources: ctg-observation-nct00569127-2026-07-29-dcf52ae95ff6]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct00569127-2026-07-29-dcf52ae95ff6]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT00569127 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was octreotide. [sources: ctg-observation-nct00569127-2026-07-29-dcf52ae95ff6-r2]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct00569127-2026-07-29-dcf52ae95ff6-r2]
ClinicalTrials.gov posted a newer version of NCT03150511, with a registry update date of 2026-11-09. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 15, 2026
Cited source date
November 9, 2026
Evidence lane
Clinical trials
Summary
Before
PeptideScanner retained ClinicalTrials.gov record NCT03150511 at 2026-07-30T18:19:48.216Z. Its registry update date was 2025-11-12, and PeptideScanner's reviewed identity mapping was tesamorelin.
After
PeptideScanner retained ClinicalTrials.gov record NCT03150511 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was tesamorelin.
1. PeptideScanner retained ClinicalTrials.gov record NCT03150511 at 2026-07-30T18:19:48.216Z. Its registry update date was 2025-11-12, and PeptideScanner's reviewed identity mapping was tesamorelin. [sources: ctg-observation-nct03150511-2025-11-12-65e14fe63370]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct03150511-2025-11-12-65e14fe63370]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT03150511 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was tesamorelin. [sources: ctg-observation-nct03150511-2025-11-12-65e14fe63370-r2]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct03150511-2025-11-12-65e14fe63370-r2]
ClinicalTrials.gov posted a newer version of NCT05093634, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 15, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials
Summary
Before
PeptideScanner retained ClinicalTrials.gov record NCT05093634 at 2026-08-13T05:52:27.024Z. Its registry update date was 2026-08-06, and PeptideScanner's reviewed identity mapping was setmelanotide.
After
PeptideScanner retained ClinicalTrials.gov record NCT05093634 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was setmelanotide.
1. PeptideScanner retained ClinicalTrials.gov record NCT05093634 at 2026-08-13T05:52:27.024Z. Its registry update date was 2026-08-06, and PeptideScanner's reviewed identity mapping was setmelanotide. [sources: ctg-observation-nct05093634-2026-08-06-24ea1a709c92]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct05093634-2026-08-06-24ea1a709c92]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT05093634 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was setmelanotide. [sources: ctg-observation-nct05093634-2026-08-06-24ea1a709c92-r2]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct05093634-2026-08-06-24ea1a709c92-r2]
ClinicalTrials.gov posted a newer version of NCT06077864, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 15, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials
Summary
Before
PeptideScanner retained ClinicalTrials.gov record NCT06077864 at 2026-08-13T05:52:27.018Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was survodutide.
After
PeptideScanner retained ClinicalTrials.gov record NCT06077864 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was survodutide.
1. PeptideScanner retained ClinicalTrials.gov record NCT06077864 at 2026-08-13T05:52:27.018Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was survodutide. [sources: ctg-observation-nct06077864-2026-08-11-60e24ca2b385]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06077864-2026-08-11-60e24ca2b385]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT06077864 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was survodutide. [sources: ctg-observation-nct06077864-2026-08-11-60e24ca2b385-r2]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06077864-2026-08-11-60e24ca2b385-r2]
ClinicalTrials.gov posted a newer version of NCT06299098, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 15, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials
Summary
Before
PeptideScanner retained ClinicalTrials.gov record NCT06299098 at 2026-08-10T18:10:03.940Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was semaglutide.
After
PeptideScanner retained ClinicalTrials.gov record NCT06299098 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide.
1. PeptideScanner retained ClinicalTrials.gov record NCT06299098 at 2026-08-10T18:10:03.940Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was semaglutide. [sources: ctg-observation-nct06299098-2026-07-21-3f43d1be33b9]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06299098-2026-07-21-3f43d1be33b9]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT06299098 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was semaglutide. [sources: ctg-observation-nct06299098-2026-07-21-3f43d1be33b9-r2]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06299098-2026-07-21-3f43d1be33b9-r2]
ClinicalTrials.gov posted a newer version of NCT06455059, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 15, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials
Summary
Before
PeptideScanner retained ClinicalTrials.gov record NCT06455059 at 2026-07-30T16:25:18.005Z. Its registry update date was 2026-01-20, and PeptideScanner's reviewed identity mapping was vosoritide.
After
PeptideScanner retained ClinicalTrials.gov record NCT06455059 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was vosoritide.
1. PeptideScanner retained ClinicalTrials.gov record NCT06455059 at 2026-07-30T16:25:18.005Z. Its registry update date was 2026-01-20, and PeptideScanner's reviewed identity mapping was vosoritide. [sources: ctg-observation-nct06455059-2026-01-20-bc7bbe888685]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06455059-2026-01-20-bc7bbe888685]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT06455059 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was vosoritide. [sources: ctg-observation-nct06455059-2026-01-20-bc7bbe888685-r2]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06455059-2026-01-20-bc7bbe888685-r2]
ClinicalTrials.gov posted a newer version of NCT06632457, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 15, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials
Summary
Before
PeptideScanner retained ClinicalTrials.gov record NCT06632457 at 2026-08-13T05:52:27.009Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was survodutide.
After
PeptideScanner retained ClinicalTrials.gov record NCT06632457 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was survodutide.
1. PeptideScanner retained ClinicalTrials.gov record NCT06632457 at 2026-08-13T05:52:27.009Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was survodutide. [sources: ctg-observation-nct06632457-2026-08-10-3a1f9c84b9ad]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06632457-2026-08-10-3a1f9c84b9ad]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT06632457 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was survodutide. [sources: ctg-observation-nct06632457-2026-08-10-3a1f9c84b9ad-r2]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06632457-2026-08-10-3a1f9c84b9ad-r2]
ClinicalTrials.gov posted a newer version of NCT06772597, with a registry update date of 2026-11-13. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 15, 2026
Cited source date
November 13, 2026
Evidence lane
Clinical trials
Summary
Before
PeptideScanner retained ClinicalTrials.gov record NCT06772597 at 2026-07-30T16:23:45.672Z. Its registry update date was 2026-02-12, and PeptideScanner's reviewed identity mapping was setmelanotide.
After
PeptideScanner retained ClinicalTrials.gov record NCT06772597 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was setmelanotide.
1. PeptideScanner retained ClinicalTrials.gov record NCT06772597 at 2026-07-30T16:23:45.672Z. Its registry update date was 2026-02-12, and PeptideScanner's reviewed identity mapping was setmelanotide. [sources: ctg-observation-nct06772597-2026-02-12-ba49a51071c7]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06772597-2026-02-12-ba49a51071c7]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT06772597 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was setmelanotide. [sources: ctg-observation-nct06772597-2026-02-12-ba49a51071c7-r2]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct06772597-2026-02-12-ba49a51071c7-r2]
ClinicalTrials.gov posted a newer version of NCT07463846, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 15, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials
Summary
Before
PeptideScanner retained ClinicalTrials.gov record NCT07463846 at 2026-08-13T05:54:14.856Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was tirzepatide.
After
PeptideScanner retained ClinicalTrials.gov record NCT07463846 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide.
1. PeptideScanner retained ClinicalTrials.gov record NCT07463846 at 2026-08-13T05:54:14.856Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was tirzepatide. [sources: ctg-observation-nct07463846-2026-08-12-3a462c76c655]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07463846-2026-08-12-3a462c76c655]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT07463846 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide. [sources: ctg-observation-nct07463846-2026-08-12-3a462c76c655-r2]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07463846-2026-08-12-3a462c76c655-r2]
ClinicalTrials.gov posted a newer version of NCT07481734, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 15, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials
Summary
Before
PeptideScanner retained ClinicalTrials.gov record NCT07481734 at 2026-07-30T16:22:22.324Z. Its registry update date was 2026-03-19, and PeptideScanner's reviewed identity mapping was tesamorelin.
After
PeptideScanner retained ClinicalTrials.gov record NCT07481734 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tesamorelin.
1. PeptideScanner retained ClinicalTrials.gov record NCT07481734 at 2026-07-30T16:22:22.324Z. Its registry update date was 2026-03-19, and PeptideScanner's reviewed identity mapping was tesamorelin. [sources: ctg-observation-nct07481734-2026-03-19-79e26d9bce31]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07481734-2026-03-19-79e26d9bce31]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT07481734 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tesamorelin. [sources: ctg-observation-nct07481734-2026-03-19-79e26d9bce31-r2]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07481734-2026-03-19-79e26d9bce31-r2]
ClinicalTrials.gov posted a newer version of NCT07487363, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 15, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials
Summary
Before
PeptideScanner retained ClinicalTrials.gov record NCT07487363 at 2026-07-30T16:22:22.342Z. Its registry update date was 2026-03-23, and PeptideScanner's reviewed identity mapping was tb-500.
After
PeptideScanner retained ClinicalTrials.gov record NCT07487363 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tb-500.
1. PeptideScanner retained ClinicalTrials.gov record NCT07487363 at 2026-07-30T16:22:22.342Z. Its registry update date was 2026-03-23, and PeptideScanner's reviewed identity mapping was tb-500. [sources: ctg-observation-nct07487363-2026-03-23-eb4b60623fcf]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07487363-2026-03-23-eb4b60623fcf]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT07487363 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tb-500. [sources: ctg-observation-nct07487363-2026-03-23-eb4b60623fcf-r2]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07487363-2026-03-23-eb4b60623fcf-r2]
ClinicalTrials.gov posted a newer version of NCT07531251, with a registry update date of 2026-11-09. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 15, 2026
Cited source date
November 9, 2026
Evidence lane
Clinical trials
Summary
Before
PeptideScanner retained ClinicalTrials.gov record NCT07531251 at 2026-08-10T18:10:04.223Z. Its registry update date was 2026-07-13, and PeptideScanner's reviewed identity mapping was elamipretide.
After
PeptideScanner retained ClinicalTrials.gov record NCT07531251 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was elamipretide.
1. PeptideScanner retained ClinicalTrials.gov record NCT07531251 at 2026-08-10T18:10:04.223Z. Its registry update date was 2026-07-13, and PeptideScanner's reviewed identity mapping was elamipretide. [sources: ctg-observation-nct07531251-2026-07-13-a3abd3798f6f]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07531251-2026-07-13-a3abd3798f6f]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT07531251 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was elamipretide. [sources: ctg-observation-nct07531251-2026-07-13-a3abd3798f6f-r2]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07531251-2026-07-13-a3abd3798f6f-r2]
ClinicalTrials.gov posted a newer version of NCT07734792, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 15, 2026
Cited source date
November 12, 2026
Evidence lane
Clinical trials
Summary
Before
PeptideScanner retained ClinicalTrials.gov record NCT07734792 at 2026-08-10T18:10:03.951Z. Its registry update date was 2026-07-29, and PeptideScanner's reviewed identity mapping was tirzepatide.
After
PeptideScanner retained ClinicalTrials.gov record NCT07734792 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide.
1. PeptideScanner retained ClinicalTrials.gov record NCT07734792 at 2026-08-10T18:10:03.951Z. Its registry update date was 2026-07-29, and PeptideScanner's reviewed identity mapping was tirzepatide. [sources: ctg-observation-nct07734792-2026-07-29-16e12449ec7c]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07734792-2026-07-29-16e12449ec7c]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT07734792 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide. [sources: ctg-observation-nct07734792-2026-07-29-16e12449ec7c-r2]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07734792-2026-07-29-16e12449ec7c-r2]
ClinicalTrials.gov posted a newer version of NCT07754461, with a registry update date of 2026-11-13. This version reports that observation; the earlier retained observation remains available as version 1.
PeptideScanner change date
November 15, 2026
Cited source date
November 13, 2026
Evidence lane
Clinical trials
Summary
Before
PeptideScanner retained ClinicalTrials.gov record NCT07754461 at 2026-08-13T05:52:27.026Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was survodutide.
After
PeptideScanner retained ClinicalTrials.gov record NCT07754461 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was survodutide.
1. PeptideScanner retained ClinicalTrials.gov record NCT07754461 at 2026-08-13T05:52:27.026Z. Its registry update date was 2026-08-10, and PeptideScanner's reviewed identity mapping was survodutide. [sources: ctg-observation-nct07754461-2026-08-10-d71d6065261a]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07754461-2026-08-10-d71d6065261a]
After
1. PeptideScanner retained ClinicalTrials.gov record NCT07754461 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was survodutide. [sources: ctg-observation-nct07754461-2026-08-10-d71d6065261a-r2]
2. This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. [sources: ctg-observation-nct07754461-2026-08-10-d71d6065261a-r2]
We added a plain-language reader guide with cited answers, re-checked the Tymlos label, and added the Drugs@FDA approval record.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
U.S. label record
After
FDA-approved as Tymlos for osteoporosis
Profile summary
Before
A parathyroid hormone-related peptide analogue. This profile cites a U.S. label record.
After
A PTHrP analogue approved by FDA as Tymlos for postmenopausal women with osteoporosis at high risk of fracture and to increase bone density in men with osteoporosis.
Evidence note
Before
The cited DailyMed label identifies Abaloparatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
After
A large randomized, placebo-controlled trial described in the label found fewer new spine fractures than placebo. The label states that abaloparatide caused osteosarcoma in rats and that it is unknown whether it does so in humans.
U.S. National Library of Medicine [sources: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19]
After
U.S. National Library of Medicine [sources: dailymed-abaloparatide-712143d9-e21e-4013-bb3b-3426a21060a8-v19]; U.S. Food and Drug Administration [sources: fda-drugs-nda208743-2017-04-28-566de3ccde8d]
We added a plain-language reader guide with cited answers, re-checked the Scenesse label, and added the Drugs@FDA approval record.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
U.S. label record
After
FDA-approved as Scenesse for erythropoietic protoporphyria
Profile summary
Before
A melanocortin analogue. This profile cites a U.S. label record.
After
A melanocortin receptor agonist approved by FDA as Scenesse to increase pain-free light exposure in adults with erythropoietic protoporphyria.
Evidence note
Before
The cited DailyMed label identifies Afamelanotide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
After
Two smaller randomized, vehicle-controlled trials described in the label found more time in direct sunlight on pain-free days than with the vehicle. The label warns of serious allergic reactions and darkening of skin, moles and freckles.
U.S. National Library of Medicine [sources: dailymed-afamelanotide-94f53286-11dd-7fbb-e053-2a95a90a7c48-v11]
After
U.S. National Library of Medicine [sources: dailymed-afamelanotide-94f53286-11dd-7fbb-e053-2a95a90a7c48-v11]; U.S. Food and Drug Administration [sources: fda-drugs-nda210797-2019-10-08-afc1f17d523d]
We added a plain-language reader guide with cited answers, published trial results from our human evidence review, and the 2026 report that renames amycretin zenagamtide.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
Investigational
After
In clinical trials; not FDA-approved
Profile summary
Before
An amylin and GLP-1 receptor agonist candidate. This profile cites a completed ClinicalTrials.gov study record.
After
An experimental Novo Nordisk GLP-1 and amylin receptor agonist, now named zenagamtide. It is not FDA-approved.
Evidence note
Before
ClinicalTrials.gov lists a Novo Nordisk oral amycretin study as completed, last updated March 5, 2025.
After
Published randomized trials, each with fewer than 300 participants, report weight loss in early studies and lower HbA1c in a Phase 2 diabetes trial, with common gastrointestinal side effects.
We added a plain-language reader guide with cited answers, re-checked the Vyleesi label, and added the Drugs@FDA approval record and FDA’s October 22, 2026 approval of a labeling supplement.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
U.S. label record
After
FDA-approved as Vyleesi for HSDD in premenopausal women
Profile summary
Before
A melanocortin receptor agonist peptide. This profile cites a U.S. label record.
After
A melanocortin receptor agonist approved by FDA as Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women.
Evidence note
Before
The cited DailyMed label identifies Bremelanotide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
After
Two large randomized trials described in the label found small improvements in desire and distress scores but no difference in satisfying sexual events. The label states that it is contraindicated in uncontrolled high blood pressure or known cardiovascular disease.
U.S. National Library of Medicine [sources: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1]
After
U.S. National Library of Medicine [sources: dailymed-bremelanotide-f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf-v1]; U.S. Food and Drug Administration [sources: fda-drugs-nda210557-2019-06-21-d4c7e45d4a54]
We added a plain-language reader guide with cited answers, published trial results from our human evidence review, current ClinicalTrials.gov records, and FDA’s current page on unapproved GLP-1 drugs (content current as of October 1, 2026), which states that cagrilintide cannot be used in compounding.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
Investigational
After
In clinical trials; not FDA-approved
Profile summary
Before
A long-acting amylin analogue under study. This profile cites a recruiting ClinicalTrials.gov record.
After
An experimental long-acting amylin analogue from Novo Nordisk, studied alone and combined with semaglutide as CagriSema. FDA says it is not an approved drug and cannot be used in compounding.
Evidence note
Before
ClinicalTrials.gov lists a Novo Nordisk pediatric study as recruiting, updated July 17, 2026.
After
A published Phase 2 trial of cagrilintide alone and large Phase 3 trials of the cagrilintide-semaglutide combination report weight loss; combination results cannot be credited to cagrilintide alone. FDA states that cagrilintide has not been found safe and effective for any condition.
We added a plain-language reader guide with cited answers, re-checked the Trulicity label, and added the Drugs@FDA approval record.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
U.S. label record
After
FDA-approved as Trulicity
Profile summary
Before
A GLP-1 receptor agonist. This profile cites a Trulicity label.
After
A GLP-1 receptor agonist approved by FDA as Trulicity for blood-sugar control in type 2 diabetes and to lower cardiovascular risk in certain adults with type 2 diabetes.
Evidence note
Before
The cited DailyMed label identifies Dulaglutide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
After
Large randomized trials described in the label support its uses, including a cardiovascular outcomes trial of 9,901 adults. The label carries a boxed warning about thyroid C-cell tumors in rats.
U.S. National Library of Medicine [sources: dailymed-dulaglutide-463050bd-2b1c-40f5-b3c3-0a04bb433309-v62]
After
U.S. National Library of Medicine [sources: dailymed-dulaglutide-463050bd-2b1c-40f5-b3c3-0a04bb433309-v62]; U.S. Food and Drug Administration [sources: fda-drugs-bla125469-2014-09-18-c02325f3972c]
We added a plain-language reader guide with cited answers drawn from the Forzinity prescribing information and FDA’s accelerated approval letter, and added the Federal Register notice of the 2024 advisory committee meeting.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
U.S. accelerated approval for a specified Barth syndrome population
After
FDA-approved as Forzinity under accelerated approval for Barth syndrome
Profile summary
Before
FDA granted Forzinity (elamipretide) accelerated approval to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg.
After
A mitochondria-targeting peptide that FDA granted accelerated approval as Forzinity to improve muscle strength in people with Barth syndrome weighing at least 30 kg.
Evidence note
Before
FDA's September 19, 2025 approval letter requires a confirmatory trial to verify clinical benefit. The approval concerns this product and specified use; a recruiting trial record does not describe its full regulatory status.
After
The approval rests on muscle-strength increases seen in the open-label extension of a 12-person trial that missed its main goals. FDA requires a randomized confirmatory trial and may withdraw the approval if benefit is not verified.
We added a plain-language reader guide with cited answers, re-checked FDA’s epitalon briefing, and added HHS’s October 30, 2026 draft enforcement-discretion policy, which lists epitalon acetate. FDA has not issued a final 503A rule.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
FDA compounding assessment in the cited records
After
Not an FDA-approved drug
Profile summary
Before
A synthetic tetrapeptide discussed in FDA briefing material for a 2026 pharmacy-compounding advisory-committee meeting.
After
A synthetic four-amino-acid peptide that is not FDA-approved. FDA’s 2026 review found only a few small human reports and no studies in people with insomnia.
Evidence note
Before
FDA's July 2026 briefing evaluates epitalon free base and acetate and distinguishes the tetrapeptide from epithalamin, a pineal-gland extract. The briefing is an advisory-process assessment, not a final regulatory determination.
After
FDA staff recommended in May 2026 against adding epitalon to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists epitalon acetate among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make epitalon an FDA-approved drug.
U.S. Food and Drug Administration [sources: fda-epitalon-briefing, fda-pcac-peptide-meeting-2026]
After
U.S. Food and Drug Administration [sources: fda-epitalon-briefing, fda-pcac-peptide-meeting-2026]; U.S. Department of Health and Human Services [sources: hhs-503a-peptide-enforcement-discretion-notice-2026]
We added a plain-language reader guide with cited answers, re-checked the generic exenatide label, added the Drugs@FDA approval records and the EXSCEL outcomes trial, and added FDA’s November 13, 2026 determination that Byetta was not withdrawn from sale for safety or effectiveness reasons.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
U.S. label record
After
FDA-approved as Byetta, Bydureon and generic exenatide
Profile summary
Before
A GLP-1 receptor agonist. This profile cites a U.S. label record.
After
A GLP-1 receptor agonist first approved by FDA as Byetta in 2005 to improve blood-sugar control in adults with type 2 diabetes.
Evidence note
Before
The cited DailyMed label identifies Exenatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
After
Randomized trials described in the label show lower HbA1c than placebo. A large outcomes trial of a longer-acting exenatide product did not show a reduction in cardiovascular events. In November 2026 FDA determined that Byetta was not withdrawn from sale for safety or effectiveness reasons.
U.S. National Library of Medicine [sources: dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17]
After
U.S. National Library of Medicine [sources: dailymed-exenatide-e6cb5c8f-e97f-4a6a-95a4-939fd2393949-v17]; U.S. Food and Drug Administration [sources: fda-drugs-nda021773-2005-04-28-80405b2e0c23, federal-register-2026-23141-024f888bd7b4]
We added a plain-language reader guide with cited answers, re-checked the Gvoke and Gvoke VialDx label, and added Drugs@FDA approval records for glucagon products.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
U.S. label record
After
FDA-approved as Gvoke, Baqsimi and other glucagon products
Profile summary
Before
A peptide hormone. The cited U.S. label distinguishes Gvoke for severe hypoglycemia from Gvoke VialDx for diagnostic use.
After
A peptide hormone that raises blood sugar, FDA-approved since 1960. The cited label covers Gvoke for severe low blood sugar and Gvoke VialDx as a diagnostic aid.
Evidence note
Before
The cited label describes subcutaneous Gvoke for severe hypoglycemia in people with diabetes aged two years and older, and intravenous Gvoke VialDx as a diagnostic aid in adults. The product, route and indication must remain distinct.
After
Smaller controlled crossover studies described in the label found that nearly all participants reached the target rise in blood sugar within 30 minutes. The label keeps the severe-hypoglycemia and diagnostic uses separate.
U.S. National Library of Medicine [sources: dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2]
After
U.S. National Library of Medicine [sources: dailymed-glucagon-359982a8-ec5c-4927-8c0f-89771e0f942b-v2]; U.S. Food and Drug Administration [sources: fda-drugs-nda212097-2019-09-10-289a38c344bd]
We added a plain-language reader guide with cited answers, re-checked the Langlara label, and added the Drugs@FDA record and FDA’s April 2026 approval letter.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
U.S. label record
After
FDA-approved as Langlara
Profile summary
Before
A long-acting insulin analogue. This profile cites a U.S. prescription label.
After
A long-acting insulin glargine product licensed by FDA as Langlara in April 2026 to improve blood-sugar control in adults and children with diabetes.
Evidence note
Before
The cited DailyMed label identifies Insulin glargine-aldy and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
After
FDA’s approval letter describes the application as seeking licensure as biosimilar to and interchangeable with US-licensed Lantus. The clinical studies in the label are insulin glargine studies against NPH insulin, not trials of insulin glargine-aldy itself.
U.S. National Library of Medicine [sources: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5]
After
U.S. National Library of Medicine [sources: dailymed-insulin-glargine-aldy-5328761e-59d3-ca7a-e063-6394a90ae810-v5]; U.S. Food and Drug Administration [sources: fda-drugs-bla761412-2026-04-29-d6855121c0c6, fda-langlara-approval-2026]
We added a plain-language reader guide with cited answers, re-checked FDA’s KPV briefing, and added HHS’s October 30, 2026 draft enforcement-discretion policy, which lists KPV acetate. FDA has not issued a final 503A rule.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
FDA compounding assessment in the cited records
After
Not an FDA-approved drug
Profile summary
Before
A tripeptide discussed in FDA briefing material for a 2026 pharmacy-compounding advisory-committee meeting.
After
A three-amino-acid peptide that is not FDA-approved. FDA’s 2026 review found no studies of KPV in people.
Evidence note
Before
FDA's July 2026 briefing evaluates KPV-related bulk drug substances for pharmacy compounding. The briefing is an advisory-process assessment, not a final regulatory determination.
After
FDA staff recommended in May 2026 against adding KPV to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists KPV acetate among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make KPV an FDA-approved drug.
U.S. Food and Drug Administration [sources: fda-kpv-briefing, fda-pcac-peptide-meeting-2026]
After
U.S. Food and Drug Administration [sources: fda-kpv-briefing, fda-pcac-peptide-meeting-2026]; U.S. Department of Health and Human Services [sources: hhs-503a-peptide-enforcement-discretion-notice-2026]
We added a plain-language reader guide with cited answers, re-checked the generic lanreotide label, and added Drugs@FDA approval records for lanreotide products.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
U.S. label record
After
FDA-approved as Somatuline Depot and other lanreotide products
Profile summary
Before
A somatostatin analogue. This profile cites a U.S. label record.
After
A somatostatin analogue first approved by FDA as Somatuline Depot in 2007. The cited label covers acromegaly, certain neuroendocrine tumors and carcinoid syndrome.
Evidence note
Before
The cited DailyMed label identifies Lanreotide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
After
Smaller randomized, placebo-controlled trials described in the label support its uses, including a tumor trial in which lanreotide lengthened progression-free survival. The cited label has no boxed warning.
U.S. National Library of Medicine [sources: dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3]
After
U.S. National Library of Medicine [sources: dailymed-lanreotide-2892b4c3-0329-4d29-97ff-3b45283bbab1-v3]; U.S. Food and Drug Administration [sources: fda-drugs-nda022074-2007-08-30-439ff00e36be]
We added a plain-language reader guide with cited answers, Drugs@FDA approval records for leuprolide products, FDA’s August 26, 2026 approval of Vobrig for central precocious puberty, and the HERO trial. DailyMed no longer serves the cited label version, so we checked it against the current rendering of the same label set.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
U.S. label record
After
FDA-approved as Lupron, Eligard, Vobrig and other leuprolide products
Profile summary
Before
A GnRH agonist. This profile cites a U.S. label record.
After
A GnRH agonist FDA-approved since 1985 under several names. The cited label covers palliative treatment of advanced prostate cancer; FDA approved Vobrig for central precocious puberty in August 2026.
Evidence note
Before
The cited DailyMed label identifies Leuprolide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
After
The label describes a controlled comparison with another hormone treatment in prostate cancer, and leuprolide served as the comparison treatment in a large randomized trial. Each leuprolide product has its own label and uses.
U.S. National Library of Medicine [sources: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10]
After
U.S. National Library of Medicine [sources: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10]; U.S. Food and Drug Administration [sources: fda-drugs-nda019010-1985-04-09-d97355079c93, fda-vobrig-approval-2026]
We added a plain-language reader guide with cited answers, re-checked the Linzess label, and added Drugs@FDA approval records for Linzess and generic linaclotide.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
U.S. label record
After
FDA-approved as Linzess
Profile summary
Before
A guanylate cyclase-C agonist peptide. This profile cites a U.S. label record.
After
A guanylate cyclase-C agonist approved by FDA as Linzess for irritable bowel syndrome with constipation and chronic constipation in adults, and for certain uses in children.
Evidence note
Before
The cited DailyMed label identifies Linaclotide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
After
Large randomized, placebo-controlled trials described in the label support its adult uses. The label carries a boxed warning: it is contraindicated in children younger than 2 because of a risk of serious dehydration.
U.S. National Library of Medicine [sources: dailymed-linaclotide-09beda19-56d6-4a56-afdc-9a77b70b2ef3-v39]
After
U.S. National Library of Medicine [sources: dailymed-linaclotide-09beda19-56d6-4a56-afdc-9a77b70b2ef3-v39]; U.S. Food and Drug Administration [sources: fda-drugs-nda202811-2012-08-30-4be8911e4fc0]
We added a plain-language reader guide with cited answers, re-checked the liraglutide label and the Drugs@FDA approval records, and added the LEADER trial report and FDA’s April 2026 503B proposal.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
U.S. label record
After
FDA-approved as Victoza, Saxenda and generic versions
Profile summary
Before
A GLP-1 receptor agonist. This profile cites a U.S. label record.
After
A GLP-1 receptor agonist approved by FDA as Victoza and Saxenda, with approved generic versions. Large randomized trials support its weight-management and cardiovascular evidence.
Evidence note
Before
The cited DailyMed label identifies Liraglutide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
After
The cited generic weight-management label covers adults and children aged 12 and older with obesity, and carries a boxed warning about thyroid C-cell tumors in rodents. FDA proposed in April 2026 to exclude liraglutide from the 503B bulks list.
U.S. National Library of Medicine [sources: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6]
After
U.S. National Library of Medicine [sources: dailymed-liraglutide-22c86976-9657-4dd0-8fff-0c3f3f08357c-v6]; U.S. Food and Drug Administration [sources: fda-drugs-nda022341-2010-01-25-97e5fbcce57e, fda-glp1-bulks-proposal-2026]
We added a plain-language reader guide with cited answers drawn from the Adlyxin and Soliqua 100/33 labels, and added the Drugs@FDA approval record for Adlyxin.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
U.S. label record
After
FDA-approved as Adlyxin and in Soliqua 100/33
Profile summary
Before
A GLP-1 receptor agonist component. This profile cites a U.S. combination-product label.
After
A GLP-1 receptor agonist approved by FDA as Adlyxin, and in combination with insulin glargine as Soliqua 100/33, to improve blood-sugar control in adults with type 2 diabetes.
Evidence note
Before
The cited DailyMed label identifies Lixisenatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
After
Large randomized trials described in the labels support these uses. In the ELIXA trial of 6,068 adults after a recent acute coronary syndrome, the results ruled out a prespecified increase in major cardiovascular risk compared with placebo.
U.S. National Library of Medicine [sources: dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25]
After
U.S. National Library of Medicine [sources: dailymed-lixisenatide-4bba538b-cf7c-4310-ae8f-cb711ed21bcc-v25]; U.S. Food and Drug Administration [sources: fda-drugs-bla208471-2016-07-27-6e0355642026, fda-adlyxin-label-2024]
We added a plain-language reader guide with cited answers, Phase 2 results from our human evidence review, and retained ClinicalTrials.gov records for Phase 3 trials.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
Investigational
After
In clinical trials; not FDA-approved
Profile summary
Before
An antibody-peptide conjugate candidate. This profile cites a completed ClinicalTrials.gov study record.
After
An experimental Amgen antibody-peptide conjugate, also called MariTide, that blocks the GIP receptor and activates the GLP-1 receptor. It is in Phase 3 trials and not FDA-approved.
Evidence note
Before
ClinicalTrials.gov lists an Amgen bioavailability study as completed, updated July 21, 2026.
After
A large 52-week randomized Phase 2 trial reported weight loss compared with placebo in people with obesity, with common gastrointestinal side effects. Phase 3 trials, including a cardiovascular outcomes trial, are registered.
We added a plain-language reader guide with cited answers, re-checked FDA’s MOTS-c briefing, and added HHS’s October 30, 2026 draft enforcement-discretion policy, which lists MOTS-c acetate. FDA has not issued a final 503A rule.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
FDA compounding assessment in the cited records
After
Not an FDA-approved drug
Profile summary
Before
A mitochondrial-derived peptide represented in FDA compounding-risk and advisory-committee records.
After
A 16-amino-acid mitochondrial peptide that is not FDA-approved. FDA’s 2026 review found no studies of MOTS-c in people.
Evidence note
Before
FDA's July 2026 briefing evaluates MOTS-c-related bulk drug substances for pharmacy compounding. The briefing is an advisory-process assessment, not a final regulatory determination.
After
FDA staff recommended in May 2026 against adding MOTS-c to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists MOTS-c acetate among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make MOTS-c an FDA-approved drug.
Related names
Before
MOTS-C
After
MOTS-C, Mitochondrial open reading frame of the 12S rRNA-c
U.S. Food and Drug Administration [sources: fda-bulk-peptide-risks, fda-mots-c-briefing, fda-pcac-peptide-meeting-2026]
After
U.S. Food and Drug Administration [sources: fda-bulk-peptide-risks, fda-mots-c-briefing, fda-pcac-peptide-meeting-2026]; U.S. Department of Health and Human Services [sources: hhs-503a-peptide-enforcement-discretion-notice-2026]
We added a plain-language reader guide with cited answers, re-checked the generic octreotide label, and added Drugs@FDA approval records and two randomized acromegaly trials from our human evidence review.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
U.S. label record
After
FDA-approved as Sandostatin and other octreotide products
Profile summary
Before
A somatostatin analogue. This profile cites a U.S. label record.
After
A somatostatin analogue first approved by FDA as Sandostatin in 1988, used for acromegaly and for diarrhea and flushing caused by certain hormone-secreting tumors.
Evidence note
Before
The cited DailyMed label identifies Octreotide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
After
The cited label states that its trials did not show improvement in symptoms or tumor size. Smaller randomized trials in acromegaly report lower growth hormone and IGF-1 levels.
U.S. National Library of Medicine [sources: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2]
After
U.S. National Library of Medicine [sources: dailymed-octreotide-387d7f8d-9762-4f6b-99e1-bdc50b8a1633-v2]; U.S. Food and Drug Administration [sources: fda-drugs-nda019667-1988-10-21-b49b130f234b]
We added a plain-language reader guide with cited answers, IMPACT trial results from our human evidence review, and retained ClinicalTrials.gov records for later trials, including a Phase 3 trial in MASH.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
Investigational
After
In clinical trials; not FDA-approved
Profile summary
Before
A glucagon/GLP-1 receptor agonist candidate. This profile cites a completed ClinicalTrials.gov study record.
After
An experimental Altimmune glucagon and GLP-1 receptor agonist studied in the liver disease MASH. It is not FDA-approved.
Evidence note
Before
ClinicalTrials.gov lists Altimmune's IMPACT study as completed, last updated May 18, 2026.
After
A 24-week randomized Phase 2 trial met its MASH-resolution goal but not its fibrosis goal. A Phase 3 trial in MASH was recruiting in August 2026.
We added a plain-language reader guide with cited answers, Phase 1 results from our human evidence review, and retained ClinicalTrials.gov records for Phase 2 and Phase 3 trials.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
Investigational
After
In clinical trials; not FDA-approved
Profile summary
Before
An amylin analogue candidate. This profile cites a ClinicalTrials.gov study record that was not yet recruiting.
After
An experimental amylin analogue from Zealand Pharma and Roche, in Phase 3 trials. It is not FDA-approved.
Evidence note
Before
ClinicalTrials.gov lists a Roche-sponsored combination study as not yet recruiting, updated July 7, 2026.
After
The only published human results reviewed here are from two small randomized Phase 1 trials, which reported weight reductions. Phase 2 trials are listed as completed without results in the sources cited, and Phase 3 trials were recruiting in late 2026.
We added a plain-language reader guide with cited answers, re-checked the Trulance label, and added the Drugs@FDA approval record.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
U.S. label record
After
FDA-approved as Trulance
Profile summary
Before
A guanylate cyclase-C agonist peptide. This profile cites a U.S. label record.
After
A guanylate cyclase-C agonist approved by FDA as Trulance for chronic idiopathic constipation and irritable bowel syndrome with constipation in adults.
Evidence note
Before
The cited DailyMed label identifies Plecanatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
After
Four large 12-week randomized, placebo-controlled trials described in the label support its uses. The label carries a boxed warning about serious dehydration in children.
U.S. National Library of Medicine [sources: dailymed-plecanatide-fe2895bf-71a6-493a-b0ca-e06b2dfefc82-v15]
After
U.S. National Library of Medicine [sources: dailymed-plecanatide-fe2895bf-71a6-493a-b0ca-e06b2dfefc82-v15]; U.S. Food and Drug Administration [sources: fda-drugs-nda208745-2017-01-19-830a6b2585ac]
We added a plain-language reader guide with cited answers, re-checked the Symlin label, and added the Drugs@FDA approval record.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
U.S. label record
After
FDA-approved as Symlin
Profile summary
Before
An amylin analogue. This profile cites a U.S. label record.
After
An amylin analogue approved by FDA as Symlin, an add-on for people with type 1 or type 2 diabetes who use mealtime insulin.
Evidence note
Before
The cited DailyMed label identifies Pramlintide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
After
Large randomized, placebo-controlled trials described in the label found modest additional HbA1c reductions. The label carries a boxed warning about severe low blood sugar when used with insulin.
U.S. National Library of Medicine [sources: dailymed-pramlintide-4aea30ff-eb0d-45c1-b114-3127966328ff-v18]
After
U.S. National Library of Medicine [sources: dailymed-pramlintide-4aea30ff-eb0d-45c1-b114-3127966328ff-v18]; U.S. Food and Drug Administration [sources: fda-drugs-nda021332-2005-03-16-bb1cb7c1a09e]
We added a plain-language reader guide with cited answers, published trial results from our human evidence review, current ClinicalTrials.gov records, and FDA’s current page on unapproved GLP-1 drugs (content current as of October 1, 2026), which states that retatrutide cannot be used in compounding.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
Investigational
After
In clinical trials; not FDA-approved
Profile summary
Before
A multi-receptor metabolic candidate. This profile cites a ClinicalTrials.gov study record that was active, not recruiting.
After
An experimental GIP, GLP-1 and glucagon receptor agonist from Eli Lilly. FDA says it is not an approved drug and cannot be used in compounding.
Evidence note
Before
ClinicalTrials.gov lists an Eli Lilly study as active, not recruiting, with a registry update posted July 20, 2026.
After
Published randomized trials, including a Phase 3 diabetes trial, report weight and blood-sugar changes over up to 48 weeks. FDA states that retatrutide has not been found safe and effective for any condition and has warned companies marketing it to consumers.
We added a plain-language reader guide with cited answers, re-checked the Wegovy label and the Drugs@FDA approval records, and added FDA’s current page on unapproved GLP-1 drugs (content current as of October 1, 2026) and its April 2026 503B proposal. An August 2026 Ozempic supplement changed carton labeling only and is not reflected.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
U.S. label record
After
FDA-approved as Ozempic, Rybelsus and Wegovy
Profile summary
Before
A GLP-1 receptor agonist. This profile cites a Wegovy label and an FDA notice.
After
A GLP-1 receptor agonist approved by FDA as Ozempic, Rybelsus and Wegovy. Its approved uses rest on large randomized trials described in the label.
Evidence note
Before
The cited DailyMed label identifies Semaglutide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
After
The Wegovy label covers weight reduction, cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight, and MASH under accelerated approval, and carries a boxed warning about thyroid C-cell tumors in rodents. FDA says compounded and other unapproved semaglutide products are not FDA-approved.
U.S. National Library of Medicine [sources: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19]
After
U.S. National Library of Medicine [sources: dailymed-semaglutide-ee06186f-2aa3-4990-a760-757579d8f77b-v19]; U.S. Food and Drug Administration [sources: fda-drugs-nda209637-2017-12-05-0b9e82eeabee, fda-unapproved-glp1-concerns-2026-r2]
We added a plain-language reader guide with cited answers, re-checked FDA’s Semax briefing, and added HHS’s October 30, 2026 draft enforcement-discretion policy, which lists Semax free base. FDA has not issued a final 503A rule.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
FDA compounding assessment in the cited records
After
Not an FDA-approved drug
Profile summary
Before
A synthetic peptide discussed in FDA briefing material for a 2026 pharmacy-compounding advisory-committee meeting.
After
A synthetic seven-amino-acid peptide that is not FDA-approved in the United States. FDA’s 2026 review found only small, incompletely reported human studies.
Evidence note
Before
FDA's July 2026 briefing evaluates Semax-related bulk drug substances for pharmacy compounding. The briefing is an advisory-process assessment, not a final regulatory determination.
After
FDA staff recommended in May 2026 against adding Semax to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists Semax free base among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make Semax an FDA-approved drug.
U.S. Food and Drug Administration [sources: fda-semax-briefing, fda-pcac-peptide-meeting-2026]
After
U.S. Food and Drug Administration [sources: fda-semax-briefing, fda-pcac-peptide-meeting-2026]; U.S. Department of Health and Human Services [sources: hhs-503a-peptide-enforcement-discretion-notice-2026]
We added a plain-language reader guide with cited answers, re-checked the Imcivree label, and added the Drugs@FDA approval record.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
U.S. label record
After
FDA-approved as Imcivree for specific rare causes of obesity
Profile summary
Before
A melanocortin-4 receptor agonist. This profile cites a U.S. label record.
After
An MC4 receptor agonist approved by FDA as Imcivree for acquired hypothalamic obesity, Bardet-Biedl syndrome and certain genetic deficiencies, not for general obesity.
Evidence note
Before
The cited DailyMed label identifies Setmelanotide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
After
A randomized, placebo-controlled trial in 142 people with acquired hypothalamic obesity and smaller open-label trials in genetic forms of obesity are described in the label. The label states that it is not indicated for general obesity.
U.S. National Library of Medicine [sources: dailymed-setmelanotide-70c3ccf7-4df0-4c75-ba07-fede9970c8d9-v14]
After
U.S. National Library of Medicine [sources: dailymed-setmelanotide-70c3ccf7-4df0-4c75-ba07-fede9970c8d9-v14]; U.S. Food and Drug Administration [sources: fda-drugs-nda213793-2020-11-25-5c2792fff70d]
We added a plain-language reader guide with cited answers, published trial results from our human evidence review, current ClinicalTrials.gov records, and FDA’s current page on unapproved GLP-1 drugs (content current as of October 1, 2026), which names survodutide among unapproved drugs sold with false research-use labels.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
Investigational
After
In clinical trials; not FDA-approved
Profile summary
Before
A glucagon/GLP-1 receptor agonist candidate. This profile cites a ClinicalTrials.gov study record that was active, not recruiting.
After
An experimental glucagon and GLP-1 receptor dual agonist from Boehringer Ingelheim, studied in obesity and fatty liver disease. It is not FDA-approved.
Evidence note
Before
ClinicalTrials.gov lists a Boehringer Ingelheim study as active, not recruiting, updated July 22, 2026.
After
Published randomized trials, including the Phase 3 SYNCHRONIZE-1 trial, report weight loss and liver-fat reductions. A completed cardiovascular safety trial has no results in the cited sources. FDA has warned companies selling unapproved survodutide with false research-use labels.
We added a plain-language reader guide with cited answers, re-checked FDA’s TB-500 briefing, added a registered trial, and added HHS’s October 30, 2026 draft enforcement-discretion policy, which lists TB-500 acetate. FDA has not issued a final 503A rule.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
FDA compounding assessment in the cited records
After
Not an FDA-approved drug
Profile summary
Before
A thymosin beta-4 fragment represented in FDA identity and pharmacy-compounding review records.
After
A synthetic seven-amino-acid fragment of thymosin beta-4 that is not FDA-approved. FDA’s 2026 review found no studies of TB-500 in people.
Evidence note
Before
FDA's July 2026 briefing evaluates TB-500-related bulk drug substances for pharmacy compounding. The briefing is an advisory-process assessment, not a final regulatory determination.
After
FDA staff recommended in May 2026 against adding TB-500 to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists TB-500 acetate among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make TB-500 an FDA-approved drug.
U.S. Food and Drug Administration [sources: fda-tb-500-identity, fda-tb-500-briefing, fda-pcac-peptide-meeting-2026]
After
U.S. Food and Drug Administration [sources: fda-tb-500-identity, fda-tb-500-briefing, fda-pcac-peptide-meeting-2026]; U.S. Department of Health and Human Services [sources: hhs-503a-peptide-enforcement-discretion-notice-2026]
We added a plain-language reader guide with cited answers, re-checked the generic teriparatide label, and added Drugs@FDA approval records for teriparatide products.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
U.S. label record
After
FDA-approved as Forteo and other teriparatide products
Profile summary
Before
A parathyroid hormone analogue. This profile cites a U.S. label record.
After
A parathyroid hormone analogue first approved by FDA as Forteo in 2002 for osteoporosis at high risk of fracture.
Evidence note
Before
The cited DailyMed label identifies Teriparatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
After
A large randomized, placebo-controlled trial described in the label found fewer new spine fractures than placebo. The label states that teriparatide caused osteosarcoma in rats; an increased risk has not been observed in human observational studies.
U.S. National Library of Medicine [sources: dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9]
After
U.S. National Library of Medicine [sources: dailymed-teriparatide-d77d40db-7f38-88eb-fd5d-4282f0642028-v9]; U.S. Food and Drug Administration [sources: fda-drugs-nda021318-2002-11-26-2f4c2df07e0a]
We added a plain-language reader guide with cited answers, re-checked the Egrifta SV label, and added the Drugs@FDA approval record.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
U.S. label record
After
FDA-approved as Egrifta for HIV-associated abdominal fat
Profile summary
Before
A growth-hormone-releasing factor analogue. This profile cites a U.S. label record.
After
A growth hormone-releasing factor analogue approved by FDA as Egrifta to reduce excess abdominal fat in adults with HIV and lipodystrophy.
Evidence note
Before
The cited DailyMed label identifies Tesamorelin and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
After
Two randomized, placebo-controlled trials described in the label found larger reductions in visceral abdominal fat than placebo. The label states that it is not indicated for weight loss and that long-term cardiovascular safety has not been established.
U.S. National Library of Medicine [sources: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9]
After
U.S. National Library of Medicine [sources: dailymed-tesamorelin-3d783378-b02d-4f19-99dd-0fc91a042224-v9]; U.S. Food and Drug Administration [sources: fda-drugs-bla022505-2010-11-10-9cc235ae6ce0]
We added a plain-language reader guide with cited answers, re-checked the Zepbound label and Drugs@FDA records, and added FDA’s August 2026 approval of a cardiovascular indication for Mounjaro, the SURPASS-CVOT label updates for Mounjaro and Zepbound, and FDA’s current page on unapproved GLP-1 drugs (content current as of October 1, 2026).
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
U.S. label record
After
FDA-approved as Mounjaro and Zepbound
Profile summary
Before
A GIP and GLP-1 receptor agonist. This profile cites a Zepbound label and an FDA notice.
After
A GIP and GLP-1 receptor agonist approved by FDA as Mounjaro and Zepbound. In August 2026 FDA added a cardiovascular risk-reduction indication for Mounjaro.
Evidence note
Before
The cited DailyMed label identifies Tirzepatide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
After
The Zepbound label covers weight reduction and obstructive sleep apnea in adults with obesity and carries a boxed warning about thyroid C-cell tumors in rats. FDA’s August 2026 letters add a cardiovascular indication for Mounjaro and SURPASS-CVOT results to both labels. FDA says compounded and other unapproved tirzepatide products are not FDA-approved.
U.S. National Library of Medicine [sources: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40]
After
U.S. National Library of Medicine [sources: dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40]; U.S. Food and Drug Administration [sources: fda-mounjaro-s044-s045-approval-2026, fda-unapproved-glp1-concerns-2026-r2]
We added a plain-language reader guide with cited answers, re-checked the Voxzogo label, and added the Drugs@FDA approval record.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
U.S. label record
After
FDA-approved as Voxzogo under accelerated approval for achondroplasia
Profile summary
Before
A C-type natriuretic peptide analogue. This profile cites a U.S. label record.
After
A C-type natriuretic peptide analogue approved by FDA as Voxzogo, under accelerated approval, to increase linear growth in children with achondroplasia whose growth plates are open.
Evidence note
Before
The cited DailyMed label identifies Vosoritide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
After
A 52-week randomized, placebo-controlled trial in 121 children described in the label found faster annual growth than with placebo. Continued approval may depend on confirmatory trials of clinical benefit.
U.S. National Library of Medicine [sources: dailymed-vosoritide-228e8560-04a4-4bb1-a81f-29531a9e4d27-v16]
After
U.S. National Library of Medicine [sources: dailymed-vosoritide-228e8560-04a4-4bb1-a81f-29531a9e4d27-v16]; U.S. Food and Drug Administration [sources: fda-drugs-nda214938-2021-11-19-6bf5863742a4]
We added a plain-language reader guide with cited answers, re-checked the Prialt label, and added the Drugs@FDA approval record.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Status
Before
U.S. label record
After
FDA-approved as Prialt for severe chronic pain
Profile summary
Before
A synthetic peptide. This profile cites a U.S. intrathecal-drug label.
After
An N-type calcium channel blocker approved by FDA as Prialt for severe chronic pain in certain adults who cannot tolerate or did not respond to other treatments.
Evidence note
Before
The cited DailyMed label identifies Ziconotide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.
After
Smaller placebo-controlled trials described in the label found greater short-term pain relief than placebo. The label carries a boxed warning about severe psychiatric symptoms and neurological impairment.
U.S. National Library of Medicine [sources: dailymed-ziconotide-b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1-v6]
After
U.S. National Library of Medicine [sources: dailymed-ziconotide-b025d8ed-937d-4597-9ad1-0b2f6e0ee5b1-v6]; U.S. Food and Drug Administration [sources: fda-drugs-nda021060-2004-12-28-20b261a9bf76]
We added a plain-language reader guide with cited answers, re-checked FDA’s BPC-157 records, added a second registered trial, and added HHS’s October 30, 2026 draft enforcement-discretion policy, which lists BPC-157. FDA has not issued a final 503A rule.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Profile summary
Before
A research peptide represented by FDA compounding-review material and one selected trial-registry record.
After
A 15-amino-acid research peptide that is not FDA-approved. FDA’s 2026 review found only a few small, short human studies.
Evidence note
Before
FDA presented BPC-157 briefing material at its July 2026 pharmacy-compounding advisory-committee meeting. Committee recommendations are nonbinding and FDA's final determination remains pending; the cited trial registration also does not establish safety or effectiveness.
After
FDA staff recommended in May 2026 against adding BPC-157 to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists BPC-157 among six peptides that may be compounded under set conditions without federal enforcement action; it does not make BPC-157 an FDA-approved drug.
U.S. Food and Drug Administration [sources: fda-bpc-157-briefing, fda-pcac-peptide-meeting-2026]; Hudson Biotech [sources: ctg-nct07437547-v1]
After
U.S. Food and Drug Administration [sources: fda-bpc-157-briefing, fda-pcac-peptide-meeting-2026]; Hudson Biotech [sources: ctg-nct07437547-v1]; U.S. Department of Health and Human Services [sources: hhs-503a-peptide-enforcement-discretion-notice-2026]
We added a plain-language reader guide with cited answers, re-checked FDA’s CJC-1295 evaluation and compounding safety-risk page, and noted that HHS’s October 30, 2026 draft enforcement-discretion policy does not include CJC-1295.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Profile summary
Before
FDA evaluates CJC-1295 and CJC-1295 with drug affinity complex (DAC) as distinct active moieties, with several salt forms.
After
A synthetic GHRH analogue that is not FDA-approved. FDA treats CJC-1295 and CJC-1295 with DAC as distinct substances and found only small, short studies in healthy adults.
Evidence note
Before
FDA's 2024 briefing distinguishes five bulk substances and reports that none is a component of an FDA-approved drug. Evidence for a DAC-modified substance cannot automatically establish effects for a non-DAC form.
After
FDA staff recommended in 2024 against adding any CJC-1295-related substance to the 503A compounding list, and FDA lists CJC-1295 among substances that may present significant safety risks. CJC-1295 is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.
U.S. Food and Drug Administration [sources: fda-bulk-peptide-risks]
After
U.S. Food and Drug Administration [sources: fda-bulk-peptide-risks]; U.S. Department of Health and Human Services [sources: hhs-503a-peptide-enforcement-discretion-notice-2026]
We added a plain-language reader guide with cited answers, re-checked FDA’s emideltide briefing and compounding safety-risk page, and noted that HHS’s October 30, 2026 draft enforcement-discretion policy does not include emideltide.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Profile summary
Before
A peptide also called DSIP in FDA briefing material for a 2026 pharmacy-compounding advisory-committee meeting.
After
A nine-amino-acid peptide, also called DSIP, that is not FDA-approved. FDA’s 2026 review found its human studies small and inconclusive.
Evidence note
Before
FDA's July 2026 briefing evaluates Emideltide-related bulk drug substances for pharmacy compounding. The briefing is an advisory-process assessment, not a final regulatory determination.
After
FDA staff recommended in 2026 against adding emideltide or emideltide acetate to the 503A compounding list. Emideltide is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.
U.S. Food and Drug Administration [sources: fda-emideltide-briefing, fda-pcac-peptide-meeting-2026]
After
U.S. Food and Drug Administration [sources: fda-emideltide-briefing, fda-pcac-peptide-meeting-2026]; U.S. Department of Health and Human Services [sources: hhs-503a-peptide-enforcement-discretion-notice-2026]
We added a plain-language reader guide with cited answers, re-checked FDA’s May 2026 503A nominations list, added FDA’s compounding safety-risk page and two randomized studies from our human evidence review, and noted that HHS’s October 30, 2026 draft enforcement-discretion policy does not include GHK-Cu.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Profile summary
Before
A copper-binding peptide named in FDA's list of bulk substances under evaluation for non-injectable compounding.
After
A copper-binding peptide that FDA lists, except in injected forms, as under evaluation for pharmacy compounding. None of the sources reviewed reports an FDA approval.
Evidence note
Before
FDA lists GHK-Cu, except injectable routes, in Category 1 for bulk substances under evaluation. That listing does not establish FDA approval, safety, or effectiveness.
After
Two randomized studies of copper-peptide skin and wound products report mixed results. FDA lists injected GHK-Cu among substances that may present significant safety risks. GHK-Cu is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.
U.S. Food and Drug Administration [sources: fda-ghk-cu-503a-2026]
After
U.S. Food and Drug Administration [sources: fda-ghk-cu-503a-2026]; U.S. Department of Health and Human Services [sources: hhs-503a-peptide-enforcement-discretion-notice-2026]
We added a plain-language reader guide with cited answers, re-checked FDA’s ipamorelin briefing and compounding safety-risk page, and noted that HHS’s October 30, 2026 draft enforcement-discretion policy does not include ipamorelin.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Profile summary
Before
FDA's August 2024 assessment distinguishes ipamorelin free base and acetate and evaluates evidence for growth hormone deficiency and postoperative ileus.
After
A synthetic five-amino-acid peptide that stimulates growth hormone release and is not FDA-approved. FDA’s 2024 review found one small randomized human trial, which showed no significant benefit.
Evidence note
Before
At the time of its assessment, FDA reported that neither form was a component of an FDA-approved drug and found insufficient evidence for the evaluated uses. The advisory briefing is not a final compounding determination.
After
FDA staff recommended in 2024 against adding ipamorelin or ipamorelin acetate to the 503A compounding list, and FDA lists ipamorelin acetate among substances that may present significant safety risks. Ipamorelin is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.
U.S. Food and Drug Administration [sources: fda-bulk-peptide-risks]
After
U.S. Food and Drug Administration [sources: fda-bulk-peptide-risks]; U.S. Department of Health and Human Services [sources: hhs-503a-peptide-enforcement-discretion-notice-2026]
We added a plain-language reader guide with cited answers, published trial results from our human evidence review, ClinicalTrials.gov records naming Innovent and Eli Lilly, and FDA’s current page on unapproved GLP-1 drugs, which names mazdutide. The status line keeps its cited China-only wording.
PeptideScanner change date
November 14, 2026
Evidence lane
Profile
Evidence note
Before
These are attributable local-government reports, not the national approval decision or complete prescribing information. The national decision and exact indication conditions remain to be reconciled. This account does not establish approval in the United States or other jurisdictions.
After
Large randomized trials in China report weight loss and lower blood sugar. The Chinese approval is reported by local-government sources, not the national approval decision or complete prescribing information. FDA lists mazdutide among unapproved drugs it has warned companies for selling with false research-use labels.
West China Hospital [sources: ctg-nct07718126-v1]; Innovent Biologics [sources: ctg-observation-nct07469800-2026-05-27-81ca4ac5542c]; U.S. Food and Drug Administration [sources: fda-unapproved-glp1-concerns-2026-r2]
We added FDA's July 2026 pharmacy-compounding review and changed the display status from identity-only to a pending safety review without implying a final FDA determination.
PeptideScanner change date
July 29, 2026
Evidence lane
Profile
Status
Before
FDA identity record only; approval status not established
After
FDA compounding safety review; final determination pending
Status classification
Before
identity-only
After
safety-review
Topic
Before
Identity records
After
Safety records
Profile summary
Before
A research-peptide name that FDA's substance registry maps to a thymosin beta-4 fragment.
After
A thymosin beta-4 fragment represented in FDA identity and pharmacy-compounding review records.
Evidence note
Before
FDA's substance registry identifies TB-500 as an N-terminal acetylated 17-23 fragment of thymosin beta-4 and explicitly states that a UNII record does not imply regulatory review or approval.
After
FDA's identity record maps TB-500 to a thymosin beta-4 fragment, while FDA's July 2026 briefing addresses its pharmacy-compounding review. Committee recommendations are nonbinding, and FDA's final determination remains pending.
We added the July 2026 FDA advisory-committee meeting context and clarified that both the committee process and the selected trial record have limited implications.
PeptideScanner change date
July 29, 2026
Evidence lane
Profile
Profile summary
Before
A research peptide with FDA compounding records and a recent trial-registry entry.
After
A research peptide represented by FDA compounding-review material and one selected trial-registry record.
Evidence note
Before
FDA's 2026 briefing says BPC-157 is not a component of an FDA-approved drug and describes limited safety information and characterization concerns. ClinicalTrials.gov also lists a recruiting study; registration is not proof of effectiveness.
After
FDA presented BPC-157 briefing material at its July 2026 pharmacy-compounding advisory-committee meeting. Committee recommendations are nonbinding and FDA's final determination remains pending; the cited trial registration also does not establish safety or effectiveness.
We added FDA's dedicated briefing and advisory-committee meeting record, while preserving the pending and nonbinding nature of the review.
PeptideScanner change date
July 29, 2026
Evidence lane
Profile
Profile summary
Before
A mitochondrial-derived peptide included in an FDA compounding-risk record.
After
A mitochondrial-derived peptide represented in FDA compounding-risk and advisory-committee records.
Evidence note
Before
FDA's compounding-risk page says it has not identified human exposure data for drug products containing MOTS-c and lacks important safety information.
After
FDA presented MOTS-c briefing material at its July 2026 pharmacy-compounding advisory-committee meeting. Committee recommendations are nonbinding, and FDA says its final determination will follow completion of the committee process and relevant reviews.
These publisher or Retraction Watch notices are registered in the reviewed Crossref snapshot for a publication used in supervised synthesis. They are not PeptideScanner corrections and do not silently alter the preserved synthesis wording.
Crossref connects notice DOI 10.1016/s0140-6736(21)01556-7 ↗ to publication DOI 10.1016/s0140-6736(21)01324-6. Registered July 17, 2021.
Crossref metadata does not by itself explain the corrected wording or establish how the publication should be interpreted. Open the bounded integrity record →
Crossref connects notice DOI 10.1016/s2213-8587(26)00157-9 ↗ to publication DOI 10.1016/s2213-8587(26)00125-7. Registered June 19, 2026 and August 1, 2026.
Crossref metadata does not by itself explain the corrected wording or establish how the publication should be interpreted. Open the bounded integrity record →
Crossref connects notice DOI 10.1016/s2213-8587(25)00399-7 ↗ to publication DOI 10.1016/s2213-8587(23)00356-x. Registered December 17, 2025 and February 1, 2026.
Crossref metadata does not by itself explain the corrected wording or establish how the publication should be interpreted. Open the bounded integrity record →
Crossref connects notice DOI 10.1038/s41591-026-04650-w ↗ to publication DOI 10.1038/s41591-026-04479-3. Registered August 25, 2026.
Crossref metadata does not by itself explain the corrected wording or establish how the publication should be interpreted. Open the bounded integrity record →
Crossref connects notice DOI 10.1016/s2213-8587(22)00051-1 ↗ to publication DOI 10.1016/s2213-8587(21)00296-5. Registered March 1, 2022.
Crossref metadata does not by itself explain the corrected wording or establish how the publication should be interpreted. Open the bounded integrity record →
Crossref connects notice DOI 10.1016/s2213-8587(22)00360-6 ↗ to publication DOI 10.1016/s2213-8587(22)00277-7. Registered February 1, 2023.
Crossref metadata does not by itself explain the corrected wording or establish how the publication should be interpreted. Open the bounded integrity record →
How version history works
PeptideScanner checks the cited record, preserves the earlier public version, and publishes a dated notice explaining the change. A factual correction identifies the error and supporting source; a routine update is labeled separately. Every published revision above comes from the same deterministic before-and-after ledger used by the profile and recent-change pages.
Representatives from GoodSir Labs publish and review PeptideScanner. PeptideScanner does not yet publish a dedicated reporting channel. A verified organization-level route will appear here before the site invites submissions; no personal contact details are exposed in the meantime.